Trial Profile

Phase 1 Clinical trial of BGE-102 for diseases associated with neuroinflammation such as Obesity.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Aug 2025 According to BioAge Labs Media release, company has completed IND-enabling studies on track for Phase 1 SAD/MAD trial initiation in 2H 2025 with initial single ascending dose (SAD) data anticipated by year-end.
29 May 2025 According to BioAge Labs Media release, plans to submit an Investigational New Drug (IND) application for BGE-102 in mid-2025. Following IND clearance, the Company expects to initiate a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial, with initial SAD data anticipated by the end of 2025.
20 Mar 2025 According to BioAge Labs Media release, company is showing progression of BGE-102, with initial clinical data expected 2H 2025 and multiple ascending dose (MAD) data anticipated in 1H 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com